This HTML5 document contains 128 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n10http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q38394471
rdf:type
wikibase:Item
schema:description
επιστημονικό άρθρο বৈজ্ঞানিক নিবন্ধ наукова стаття, опублікована в березні 2016 artículu científicu espublizáu en 2016 научна статия мақолаи илмӣ vitskapeleg artikkel artikull shkencor 2016年論文 2016年论文 artykuł naukowy artigo científico 2016年論文 scientific article published on 18 March 2016 სამეცნიერო სტატია مقالة علمية نشرت في 18 مارس 2016 2016年论文 article scientific tieteellinen artikkeli artikel ilmiah articolo scientifico научни чланак บทความทางวิทยาศาสตร์ artigo científico 2016年論文 2016年论文 vědecký článek article científic vetenskaplig artikel bilimsel makale videnskabelig artikel 2016 nî lūn-bûn scientific article published on 18 March 2016 wetenschappelijk artikel 2016年の論文 2016年论文 2016年論文 מאמר מדעי naučni članak научная статья scienca artikolo artikulong pang-agham 2016年論文 artículo científico 2016년 논문 bài báo khoa học artigo científico tudományos cikk vitenskapelig artikkel vedecký článok article scientifique 2016年论文 teaduslik artikkel articol științific scientific article published on 18 March 2016 2016年论文 научни чланак wissenschaftlicher Artikel
p:P577
wds:Q38394471-EB4739A1-3583-4E1B-BBE7-34E67FBE4ECC
wdt:P577
2016-03-18T00:00:00Z
p:P2093
wds:Q38394471-247CAF90-0996-416F-8A01-AECA4237FD03 wds:Q38394471-3D1C6D9C-2C58-4159-844A-E4090F5406C8 wds:Q38394471-7E9A4079-1D56-41C9-BD1F-D4F5DF59CF73
wdt:P2093
Takahiro Hayashi Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators Kazuo Kimura
rdfs:label
Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia
skos:prefLabel
Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia
schema:name
Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia
p:P50
wds:Q38394471-0BAB4F3A-1C86-4748-9509-965A5D6D72CF wds:Q38394471-1C23259A-7B04-4112-BC4D-2459E20D3C81 wds:Q38394471-8BF93B36-32CB-4317-87A0-A476B7E49B24 wds:Q38394471-8C8D05C0-4D42-4A3B-91E0-FB04C7945A75 wds:Q38394471-8DBD8E39-03C2-4C4D-B5E3-5B2A7094E2A7 wds:Q38394471-6007384E-904A-41F7-82DB-F389D9D360A8 wds:Q38394471-6A208BDC-3383-46F3-8D61-092B9A3E1016 wds:Q38394471-6C3778DF-265C-473E-94BF-9F2CBBE4C7D5 wds:Q38394471-75A91136-CD42-45C2-8D04-62E5C1B264D9 wds:Q38394471-4DFCB920-B34D-4CE1-BE6F-CFD159C26B85 wds:Q38394471-56EC3695-4E3A-42DB-BA67-95C69695F3FA wds:Q38394471-42F9C774-B700-43D0-AABD-6D1980F4EEE9 wds:Q38394471-4478D901-69B8-4D68-8F8A-78FB2C809C2C wds:Q38394471-CEAB37B4-B376-4374-90B7-59D9ECBB453C wds:Q38394471-E53159A0-4B15-4F42-94A8-F4525ECD24F2 wds:Q38394471-A48B30E3-0829-4A6D-907C-FDBEA1C9FA91 wds:Q38394471-B0F74041-9F9A-49AE-99AB-EE9504AD8B93
wdt:P50
wd:Q117250727 wd:Q117250726 wd:Q117250729 wd:Q117250723 wd:Q117250728 wd:Q117250731 wd:Q117250730 wd:Q114427064 wd:Q88294906 wd:Q117249938 wd:Q117250705 wd:Q96222993 wd:Q87209536 wd:Q87209551 wd:Q117250722 wd:Q117250725 wd:Q117250724
p:P1476
wds:Q38394471-98EDADCB-B378-49F2-BF87-F6694CAEFC79
wdt:P1476
Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia
p:P304
wds:Q38394471-FFDF2AEC-5542-496C-A184-69F16110B1C2
wdt:P304
169-175
p:P31
wds:Q38394471-5A948A3F-DA7B-4C04-8A0D-E6899038635C
wdt:P31
wd:Q13442814
p:P698
wds:Q38394471-511A8F02-6109-4923-A781-F6EDE4281520
wdtn:P698
n9:27005768
wdt:P698
27005768
p:P1433
wds:Q38394471-E05A207C-0927-4CC3-A3B4-007B5F9DB292
wdt:P1433
wd:Q15816342
p:P433
wds:Q38394471-BD308F1D-8028-47BC-9721-BF87DD3E9A63
p:P478
wds:Q38394471-FA682AFC-4428-4100-81FB-EAF1BC052A72
wdt:P433
1
wdt:P478
69
p:P356
wds:Q38394471-2B3094CF-D597-49AD-8C73-EDF564907983
wdtn:P356
n10:J.JJCC.2016.02.015
wdt:P356
10.1016/J.JJCC.2016.02.015